EP Patent

EP3541389A1 — Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer

Assigned to Pfizer Inc · Expires 2019-09-25 · 7y expired

What this patent protects

This invention relates to a method of treating non-small cell lung cancer by administering an EGFR T790M inhibitor in combination with a CDK inhibitor to a patient in need therof.

USPTO Abstract

This invention relates to a method of treating non-small cell lung cancer by administering an EGFR T790M inhibitor in combination with a CDK inhibitor to a patient in need therof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3541389A1
Jurisdiction
EP
Classification
—
Expires
2019-09-25
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.